Semler Scientific (NASDAQ:SMLR) Posts Quarterly Earnings Results, Beats Expectations By $5.31 EPS

Key Points

• Semler Scientific reported earnings of $5.04 per share, significantly exceeding expectations by $5.31 EPS, compared to the consensus estimate of ($0.27).
• The company's stock increased by 2.6%, reaching $35.37 during mid-day trading, with a current market capitalization of $487.68 million.
• Analysts have mixed ratings on Semler Scientific, with one "sell" rating and several "buy" ratings, leading to a consensus rating of "Moderate Buy" and a target price of $82.00.

Semler Scientific (NASDAQ:SMLR - Get Free Report) posted its quarterly earnings results on Monday. The company reported $5.04 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $5.31, Zacks reports. Semler Scientific had a negative net margin of 60.69% and a positive return on equity of 19.75%.

Semler Scientific Stock Up 2.6%

Semler Scientific stock traded up $0.91 during mid-day trading on Monday, reaching $35.37. 568,922 shares of the company's stock were exchanged, compared to its average volume of 696,709. The company has a market cap of $487.68 million, a P/E ratio of -13.55 and a beta of 1.34. Semler Scientific has a twelve month low of $21.77 and a twelve month high of $81.56. The company has a quick ratio of 0.51, a current ratio of 0.52 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average of $38.02 and a 200-day moving average of $40.01.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SMLR. Benchmark began coverage on shares of Semler Scientific in a research report on Tuesday, July 8th. They set a "buy" rating and a $101.00 price objective for the company. Maxim Group raised shares of Semler Scientific to a "strong-buy" rating and set a $95.00 price objective for the company in a research report on Wednesday, July 9th. Wall Street Zen cut shares of Semler Scientific from a "buy" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Cantor Fitzgerald began coverage on shares of Semler Scientific in a research report on Monday, July 28th. They set an "overweight" rating and a $61.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Semler Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $82.00.

Institutional Investors Weigh In On Semler Scientific

A number of hedge funds have recently added to or reduced their stakes in SMLR. Royal Bank of Canada lifted its holdings in Semler Scientific by 101.2% during the 1st quarter. Royal Bank of Canada now owns 43,977 shares of the company's stock worth $1,592,000 after buying an additional 22,123 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Semler Scientific by 71.7% in the 1st quarter. AQR Capital Management LLC now owns 15,251 shares of the company's stock valued at $552,000 after purchasing an additional 6,371 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Semler Scientific by 47.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,965 shares of the company's stock valued at $144,000 after purchasing an additional 1,269 shares in the last quarter. 49.37% of the stock is currently owned by institutional investors and hedge funds.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.